Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision MedicineChantal Pauli, Mark A. Rubin, Benjamin D. Hopkins et al.|Cancer Discovery|2017Cited by 964
Patient derived organoids to model rare prostate cancer phenotypesLoredana Puca, Himisha Beltran, Rohan Bareja et al.|Nature Communications|2018Cited by 364
Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized TherapyVignesh Narasimhan, Susan L. Woods, Josephine A. Wright et al.|Clinical Cancer Research|2020Cited by 185
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancerGoldie Y.L. Lui, Carla Grandori, Reid Shaw et al.|EBioMedicine|2020Cited by 38
Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell CarcinomaShogo Shigeta, Christopher J. Kemp, Goldie Y.L. Lui et al.|Molecular Cancer Therapeutics|2021Cited by 30